Application of cannabidiol in preparation of medicine for treating non-Hodgkin lymphoma

A non-Hodgkin and cannabidiol technology, applied in the field of biomedicine, can solve the problems affecting the curative effect and disease outcome, poor prognosis and toxic effects of relapsed or refractory non-Hodgkin's lymphoma patients

Pending Publication Date: 2022-03-04
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

During the course of treatment, chemotherapy and radiotherapy, due to their cytotoxicity, will kill tumor cells and also have toxic effects on normal cells during their application, causing patients to experience various degrees of side effects during chemotherapy and radiotherapy, resulting in The quality of life of patients is generally reduced, and even the treatment is forced to be discontinued due to intolerance, which seriously affects the curative effect and the outcome of the disease
Immunotherapy mainly includes two aspects of cell therapy and antibody therapy. This treatment method mainly activates the body's own immune response to kill tumor cells by increasing tumor antigenicity and regulating tumor immune escape. Treatment helps, but prognosis remains poor for patients with relapsed or refractory non-Hodgkin lymphoma after initial treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cannabidiol in preparation of medicine for treating non-Hodgkin lymphoma
  • Application of cannabidiol in preparation of medicine for treating non-Hodgkin lymphoma
  • Application of cannabidiol in preparation of medicine for treating non-Hodgkin lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1. The inhibitory effect of cannabidiol (CBD) on the survival of human non-Hodgkin's lymphoma cell line Jeko-1 in vitro

[0030] Cannabidiol (CBD) was dissolved in DMSO to a concentration of 50 μM and stored at -20°C until use. Cannabidiol (CBD) was further diluted to the desired concentration before use, and the DMSO concentration was determined to be less than 0.001%. The human non-Hodgkin's lymphoma cell Jeko-1 used in this experiment was used as the test cell. The cells were cultured at 37°C in a humidified atmosphere of 5% CO2 and 95% air in RPMI-1640 containing 10% heat-inactivated fetal bovine serum. The survival of human non-Hodgkin's lymphoma cells Jeko-1 was tested at different concentrations of cannabidiol (CBD).

[0031] result: figure 1 The survival of human non-Hodgkin's lymphoma cells Jeko-1 when administered with cannabidiol (CBD) is described. It can be seen that as the dose of cannabidiol (CBD) increased, the survival rate of the lymphoma c...

Embodiment 2

[0032] Example 2. The inhibitory effect of cannabidiol (CBD) on the survival of human non-Hodgkin's lymphoma cells REC1 in vitro

[0033]Cannabidiol (CBD) was dissolved in DMSO to a concentration of 50 μM and stored at -20°C until use. Cannabidiol (CBD) was further diluted to the desired concentration before use, and the DMSO concentration was determined to be less than 0.001%. The human non-Hodgkin's lymphoma cell REC1 used in this experiment was used as the test cell. The cells were cultured at 37°C in a humidified atmosphere of 5% CO2 and 95% air in RPMI-1640 containing 10% heat-inactivated fetal bovine serum. The survival of human non-Hodgkin's lymphoma cells REC1 was tested at various concentrations of cannabidiol (CBD).

[0034] result: figure 2 Survival of human non-Hodgkin's lymphoma cells REC1 in response to cannabidiol (CBD) administration is described. It can be seen that as the dose of cannabidiol (CBD) increased, the survival rate of the lymphoma cells decrea...

Embodiment 3

[0035] Example 3. Cytotoxicity of cannabidiol (CBD) on monocytes isolated and cultured from healthy human peripheral blood and human non-Hodgkin's lymphoma cells (Jeko-1, REC1) in vitro

[0036] The concentration of cannabidiol (CBD) used in this example was 20 μM. In this experimental example, different human non-Hodgkin's lymphoma cells (Jeko-1, REC1) and monocytes isolated and cultured from peripheral blood of healthy people were used as test cells. The specific operation steps for extracting mononuclear cells from peripheral blood collected from normal volunteers are as follows: (1) Dilute the collected anticoagulated blood with an equal amount of normal saline; (2) Add Lymphoprep lymphocytes equal to the volume of blood in a 15ml centrifuge tube Cell separation solution, and add diluted blood, the separation solution should be in the lower layer to avoid mixing of blood and separation solution; (3) Centrifuge at 800 × g in a horizontal rotor for 20 minutes at room tempera...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of cannabidiol in preparation of a medicine for treating non-Hodgkin lymphoma. The invention provides a novel medical application of cannabidiol (CBD), which can effectively reduce the survival rate of human non-Hodgkin lymphoma cells, does not influence the survival of normal cells under the effective dosage of the CBD on the lymphoma cells, and provides a potential medicine for treating the non-Hodgkin lymphoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of cannabidiol (CBD) in the preparation of products for treating non-Hodgkin's lymphoma. Background technique [0002] Lymphoma is a type of malignant tumor originating from the lymph nodes and lymphoid tissues of the hematopoietic system. According to the statistics of the World Health Organization, the annual growth rate of the incidence of lymphoma is 7.5%, and the incidence rate has increased rapidly in recent years. According to its pathological characteristics, lymphoma is mainly divided into two categories: Hodgkin's lymphoma and non-Hodgkin's lymphoma. Judging from the current data, Hodgkin's lymphoma usually has a better treatment effect and a higher cure rate. Non-Hodgkin lymphoma is a group of highly heterogeneous malignant lymphoproliferative diseases, and it is one of the most common malignant tumors in men in my country. The exact etiology o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/05A61K36/60A61P35/00
CPCA61K31/05A61K36/60A61P35/00
Inventor 冯敏张寒
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap